Treace Medical Concepts Slides After Cut to Full-Year Revenue Outlook

Dow Jones

Nov 08

By Terell Wright

Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries.

Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%.

The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet.

Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery.

The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share.

Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million.

Write to Terell Wright at terell.wright@wsj.com

(END) Dow Jones Newswires

November 07, 2025 15:05 ET (20:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581836445"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581836445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581836445?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-08 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581836445","market":"hk","top_or_hot":-1,"title":"Treace Medical Concepts Slides After Cut to Full-Year Revenue Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Terell Wright \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries. \n</p>\n<p>\n  Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%. \n</p>\n<p>\n  The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet. \n</p>\n<p>\n  Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery. \n</p>\n<p>\n  The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share. \n</p>\n<p>\n  Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Terell Wright at terell.wright@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 07, 2025 15:05 ET (20:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Treace Medical Concepts Slides After Cut to Full-Year Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTreace Medical Concepts Slides After Cut to Full-Year Revenue Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-08 04:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Terell Wright \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries. \n</p>\n<p>\n  Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%. \n</p>\n<p>\n  The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet. \n</p>\n<p>\n  Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery. \n</p>\n<p>\n  The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share. \n</p>\n<p>\n  Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Terell Wright at terell.wright@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 07, 2025 15:05 ET (20:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMCI","symbol_name":"Treace Medical Concepts, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2581836445","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581836445","pubTimestamp":1762545900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries.Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%.The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet.Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery.The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share.Revenue rose 11%, to $50.2 million, ahead","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TMCI":"Treace Medical Concepts, Inc."},"translate_title":"Treace Medical Concepts下调全年收入预期后股价下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMCI":1.5},"content_text":"By Terell Wright \n\n\n \n\n\n  Shares of Treace Medical Concepts fell after the medical-technology company lowered its full-year revenue outlook, citing softening customer demand for elective bunion surgeries. \n\n\n  Shares fell 34%, to $4.10, midday Friday, after touching a new 52-week low earlier in the day. Year-to-date, shares are down nearly 45%. \n\n\n  The company on Thursday cut its full-year revenue guidance to a range of $211 million to $213 million, from a prior range of $224 million to $230 million. Analysts expected $216.9 million, according to FactSet. \n\n\n  Chief Executive John Treace said the company lowered its outlook because shifting surgeon and patient preferences favor minimally invasive solutions, and economic conditions are causing patients to defer elective bunion surgery. \n\n\n  The Ponte Vedra Beach, Fla., company's third-quarter loss widened to $16.3 million, or 26 cents a share, from $15.4 million, or 25 cents a share, a year earlier. Analysts expected a loss of 28 cents a share. \n\n\n  Revenue rose 11%, to $50.2 million, ahead of Wall Street's estimate for $49.8 million. \n\n\n \n\n\n  Write to Terell Wright at terell.wright@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 15:05 ET (20:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}